Publications by authors named "Michael Larbig"

Claim this Profile
E
Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19.
Alberto Papi, Renee D Stapleton, Paul M Shore, Mihai Alexandru Bica, Younan Chen, Michael Larbig

Lung· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β-agonist in UK primary care settings.
Roland Buhl, Liam G Heaney, Emil Loefroth, Michael Larbig, Konstantinos Kostikas

Respir Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
Stefan M Frent, Kenneth R Chapman, Michael Larbig, Alexander Mackay, Robert Fogel

Am J Respir Crit Care Med· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Kenneth R Chapman, John R Hurst, Stefan-Marian Frent, Michael Larbig, Robert Fogel

Am J Respir Crit Care Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Antonio R Anzueto, Konstantinos Kostikas, Karen Mezzi, Steven Shen, Michael Larbig

Respir Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.
Veit J Erpenbeck, Eva Vets, Lien Gheyle, Wande Osuntokun, Michael Larbig

Clin Pharmacol Drug Dev· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Facial thermography is a sensitive tool to determine antihistaminic activity: comparison of levocetirizine and fexofenadine.
Michael Larbig, Bernard Burtin, Laurent Martin, Holger Stamm, Birgit Luettig

Br J Clin Pharmacol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Toll-like receptor-2/6 agonist macrophage-activating lipopeptide-2 cooperates with IFN-gamma to reverse the Th2 skew in an in vitro allergy model.
Henning Weigt, Peter F Muhlradt, Michael Larbig, Norbert Krug, Armin Braun

J Immunol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis